uniQure Shares Surge After FDA Reverses Course on Huntington's Gene Therapy Filing

uniQure shares surged on June 17 after the company said the U.S. Food and Drug Administration had reversed an earlier position on its Huntington's disease gene therapy, AMT-130.

Coverage across the day said the stock jumped roughly 78% to 81% intraday as investors reacted to a regulatory shift that could materially shorten the path to a filing for the treatment.

The key change is that the FDA will now allow uniQure to pursue a filing using limited Phase I and Phase II clinical data, according to multiple reports. That is a significant departure from the agency's earlier stance in 2025, when it said the available early-stage data would not be enough and pushed for more evidence before any submission.

What changed

The revised position removes a major hurdle for uniQure's plan to seek approval through a Biologics License Application, or BLA. Earlier coverage said the agency had been expecting more data, including a new placebo-controlled trial, before it would be willing to review the program.

Barron's first reported that the FDA had agreed to consider limited Phase I and II data for AMT-130. Investor's Business Daily later reported that the company could refile using three-year clinical data. By later in the day, The Wall Street Journal reported that the FDA had reversed course and allowed uniQure to proceed without another trial.

The wording varied across reports, but the common thread was the same: the FDA appears to have moved from rejection of the existing evidence package to acceptance of a much leaner submission path.

Why AMT-130 matters

AMT-130 is uniQure's Huntington's disease gene therapy candidate. Huntington's is a rare inherited neurodegenerative disorder, and drug development in the disease has long been difficult because patient populations are small and trials are hard to run.

That makes the FDA's apparent flexibility especially important. If the company can file on the basis of the current dataset, it may be able to reach the next regulatory step sooner than investors had expected just hours earlier.

uniQure is a Dutch gene-therapy company best known in the U.S. for Hemgenix, its approved hemophilia B therapy. AMT-130 has been one of its most closely watched pipeline assets, in part because earlier FDA expectations had left the program facing a slower and more uncertain path.

Market reaction and investor read-through

The stock reaction showed how material the change was to the market. A move of roughly four-fifths in a single session signaled that investors viewed the reversal as more than a procedural adjustment.

Analysts cited in the coverage framed the decision as a possible sign of greater flexibility from the FDA in rare-disease gene therapy, where small patient populations and difficult trial designs can make traditional development pathways harder to execute.

The move may also have implications beyond uniQure. Coverage noted the possibility that sentiment could spill over to other Huntington's disease and gene-therapy developers if investors conclude the agency is willing to accept less conventional evidence packages in some rare-disease settings.

What remains unresolved

Several important details are still unclear. It is not yet confirmed whether the FDA will require a confirmatory study after submission, what exact endpoint or dataset will anchor the BLA, or whether the agency has issued formal language that uniQure has disclosed in a press release or filing.

The coverage also leaves some ambiguity in the precise framing of the FDA's decision. Some reports described the agency as agreeing to consider limited Phase I and II data, while others said it would allow a resubmission using three-year clinical data.

Those differences matter because they affect how quickly uniQure could move and how strong the regulatory runway really is. For now, the clearest takeaway is that the company has gained a substantially better shot at filing than it had under the FDA's earlier position.

Chronology of the shift

The timeline highlights how fast the story moved. In November 2025, the FDA had said uniQure's existing Huntington's data were not sufficient and signaled that more evidence would be needed.

On June 17, 2026, Barron's reported that the stock was already surging after the FDA's surprise change in tone. Later, Investor's Business Daily said the company could refile using three-year clinical data.

By 20:48 UTC, The Wall Street Journal said the FDA had reversed course and allowed uniQure to move ahead without another trial. That sequence suggests the market was reacting in real time to a regulatory development that emerged and was then corroborated across multiple outlets over the course of the day.

Broader significance

For Huntington's disease patients and advocates, the change matters because it could bring a potential treatment closer to submission. For investors, it reduces one of the biggest regulatory risks in uniQure's program.

More broadly, the episode adds to scrutiny of how flexibly the FDA is applying evidence standards in rare-disease gene therapy. If the new position holds, it could become an important precedent for other developers trying to bring highly targeted therapies through a difficult approval process.

The next confirmation points are straightforward: an official uniQure filing or press release with the exact FDA language, and any clarification from the agency on whether a confirmatory study is still expected.